			r	age I of I	
Form PTO-1449 (modified)	Ţ	Atty. Docket No. UTSC584	Serial No. 07/12	2,427	
List of Patents and Publications for Information Disclosure S	••	Applicant Yiyu Zou et al			
(Use several sheets if necessa	ıry)	Filing Date: 07/24/98	Group:	09/1	
U.S. Patent Documents	Foreign	Patent Documents	Other Art		
See Page 1		See Page 1	See Page 1	Page 1	
	U.S. Pate	ent Documents			

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date if App.
	Al	4,855,090	8/8/89	Wallach	264	4.1	
W	A2	4,911,928	3/27/90	Wallach	424	450	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
M	B1	WO86/00238	1/16/86	WIPO	B01D	13/00	
	B2	0 220 797 A2	5/6/87	Europe	A61K	9/50	Yes
	В3	0 140 085 A2	5/8/85	Europe	A61K	9/50	Yes
	B4	0 193 414 A2	9/3/86	Europe	A61K	9/50	Yes
	B5	WO92/11842	7/23/92	PCT	A61K	9/127	Yes
	В6	JP6293615	8/25/92	Japan			
	В7	JP6227966	1/29/93	Japan			
	В8	JP6183953	6/24/91	Japan	_	-	
	В9	WO89/11850		PCT		_	
	B10	6-227966		Japan		-	Yes
	B11	6-183953		Japan	<u></u>	-	Yes
,	B12	60-155109		Japan			Abstract

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation						
111	C1	Japanese Abstract, JP 62-93615 A (Nippon Oils & Fats Co. Ltd.), Oct. 21, 1994						

Examiner:	Lida	DATE CONSIDERED:	3/91

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form P	TO-	144	9 (Modified)		Atty Docket No.		erial No.	
List o	f P	ate	nts and Publi		CSC584 Applicant			
For Ap	pli	can	t's Informati	ion	Applicant			
Discro	sur	e s	statement	Yiv	u Zou et al			
(Use s	eve	ral	sheets if ne	ecessary)	Filing Date 7/24/98		Froup	
					772.17 50			
	Ref	ere	nce Designat:	ion	U. S. Patent Docur	nents		Intat Data
Examin	er		Document			03	Cubalaga	Filing Date If Appropriate
<u>Initia</u>			Number	Date	Name Lenk et al	Class 424	450	1/14/91
_ by	_		5,178,875	1/12/93	Priebe et al	514	34	5/30/89
	_		5,132,290	7/21/92		424	450	2/23/89
	igcup		5,032,404	7/16/91	<u> </u>		450	11/10/88
	\sqcup		4,999,199	3/12/91	Anaissie et al	424		10/16/87
	igsquare	ΑE	4,950,432	8/21/90	Mehta et al	264	4.6	
	\sqcup	AF	4,863,739	9/5/89	Perez-Soler etal		450	5/19/87
		AG	4,812,312	3/14/89		424	417	3/3/87
		AH	4,537,882	8/27/85	Horton et al	514	34	5/10/84
	. İ	AI	4,311,712	1/19/82	Evans et al	424	365	8/20/79
	<i>T</i> i	AJ	4,201,773	5/6/80	Horton et al	424	180	7/26/78
	7 i	AK	4,522,803	6/11/85	Lenk et al	424	1.1	3/24/83
7								
				FOREIGN PAT	ENT DOCUMENTS			Translation
Examir Initia			Document Number	Date	Country	Class	Subclass	Yes/No
Initia	-	AT.	0,282,405	9/14/88	European			
$-\omega$			6,183,953	7/5/94	Japan			Abstract
			6,227,966	8/16/94	Japan		L	Abstract
			0,613,685	9/7/94	Europe			Abstract
	7		2,700,954	8/5/94	France	Ī	<u> </u>	Abstract
——∀		AP	2,700,934	10/3/31				•
	O	ישני	R ART (Includ	ing Author, T	itle, Date Pertin	ent Pa	ges, Etc.)	
	<u> </u>		Darez-Soler	et al. "Anthr	acycline Antibiot	1CS W1	ch High Li	posome Entrap-
- 1.			ment: Struct	ural Features	and Biological A	ctivit	y," Cancer	Research 50:
h	1	AR		7 45 70001				
			Zou et al, ".	Antitumor Act	<u>ivity of Free and</u>	Lipos	ome-entrap	ped Annamycin,
	1		A Lipophilic	Anthracyclir	ne Antibiotic with	Non-C	ross-Resis	tance Pro
		AS	perties, " Ca	ncer Research	1 54:1479-1484 (Ma	rch 15	, 1994).	auth American
	1		McCutcheon's	"Emulsifiers	& Detergents, " V	<u>ol. 1, </u>	p. 201, N	orth American
	1		Edition (199					
	-T	AT						Chabilized
	$-\sqrt{i}$		Kronberg et	al, "Preparat	ion and Evaluatio	n or S	Macrophag	e Untake, and
	٧.		<u>Liposomes: C</u> Toxicity," J	Olloidal Star	oility, Serum Stab	1990).	Macrophag	C Opcarro,
Exami			TOXICITY, J	. Pharm. SCI	Date Considered		- 6	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	-		Kehr			51	<u> </u>	
EXAMI	NER	: I	nitial if ref	erence consid	dered, whether or	not ci	tation is	in conformance
N	MDE	20	o. Draw line	through cital	tion if not in con	ILOI man	ce and not	. COMBINETEN.
Inclu	de (cop	y of this for	m with next of the mext of the	communication to a	State	mentPTO-	1449 (Modified)
							P	Added page

Form PTO-1449 (Modified) List of Patents and Publications			Atty Docket No. Serial No. UTSC584					
		nt's Informat Statement	ion		Applicant			
DISCIOSA		oca comenc		Yiy	u Zou et al			
(Use sev	eral	l sheets if n	ecessary)	(Filing Date 07/24/98		Group	
							-	
		ence Designat	ion	1	U.S. Patent Docu	ments	1	Iriling Date
Examiner Imitial		Document Number	Date		Name	Class	Subclass	Filing Date If Appropriate
17/1/	AA	4,558,579	12/17/85		Fountain et al	72	56	11/16/83
7/0	•	4,975,282	12/4/90		Cullis et al	424	450	11/17/87
1/	AC					<u> </u>	<u> </u>	
	AD					<u>i </u>	<u> </u>	
	AE		<u></u>			İ	<u> </u>	
	AF		İ			Ĭ	İ	
	AG					İ		
	AH		Ì			<u> </u>	<u> </u>	
	AI		Ī			<u> </u>		
	AJ					<u> </u>	<u> </u>	
	AK					<u> </u>		
					DATE DAGENER			
Examiner	1	Document	FOREIGN	PA'I'I	ENT DOCUMENTS	1	1	Translation
Initial		Number	Date		Country	Class	Subclass	Yes/No
	AL	WO 87/00238	1/16/86		PCT			
	AM	87/00043	1/15/87		PCT			
1//	AN	60-155109			Japanese			
	AO					<u> </u>		
	AP					<u> </u>		
		(7 7			iele Desemble	ant D	and Etal	
	THEI	Singer et al	ing Autnor "Time- a	nd I	<u>itle, Date Pertin</u> Dose-dependent Ch	anges	in Ejection	n Fraction
1	 				e Angiography Aft			
W		Cancer Treat	m. Rep., 6	2 (6)):945-948 (1978).			
\rightarrow \rightarrow	1	<u>Herman et al</u>	, "Prevent	ion	of Chronic Doxor	<u>ubicir</u>		
1	İ	Beagles by L	iposomal E	nca	osulation," Cance	r Res	43:5427-5	432 (1983)
	AS				<u></u>			
					Clinical Trial an			
1		Liposome-Enc	apsulated_	Dox	orubicin," J. Cli	n. One	:ol. 8:1093	-1100
	AT	(1990).			Circulation Time	and I	Thangod No.	cumulation in
1	!	Gabizon et a						
() /	 				orubicin Encapsul			reme-diycor
Examiner	•	1.1	omes," Can	cer	Research 54:987-	1 3 3 2 1.	۸. ا	
		Krder			.	<u>`````````````````````````````````````</u>	191	
EXAMINER	: II	nitial if ref	erence cor	sid	ered, whether or	not c	itation is	in conformance
with MPE	P609	e; Draw line	cnrough ci	tat ct c	ion if not in cor	applic	nce and not	COMSTRETEG.
THETHUE	COD	Y OI CHIS TOL	Ir	for	mation Disclosure	State	ementPTO-	
							A	dded page

Form PTO-1449 (Modified) List of Patents and Publications For Applicant's Information Disclosure Statement		_U	Atty Docke SC584 Applicant	t No.		Serial No.			
Disciosu	re	statement		Viv	u Zou et al				
(Use sev	era:	l sheets if n	ecessary)		Filing Dat 7/24/98			Group	
				L	-,,				
		<u>ence Designat</u>	ion		<u>U.S.Pater</u>	t Docu	ments		
Examiner		Document					01	0	Filing Date
<u>Initial</u>	AA	Number	<u>Date</u>	-	Name		Class	Subclass	If Appropriate
	AB	I			ł		- 	 	
	•		ļ		<u> </u>	,	 	1	
	AC	•	ļ		<u> </u>		 	<u> </u>	
	AD				<u> </u>		 	<u> </u>	<u> </u>
	AE		<u> </u>				 	<u> </u>	
	AF						<u> </u>	<u> </u>	
	AG		<u> </u>				↓		
	AH						<u> </u>	ļ	
	AI	<u> </u>	<u> </u>				1		
	AJ							<u> </u>	
	AK		<u> </u>				1		
Examiner	i i	Document	<u>FOREIGN</u>	PAT	<u>ENT DOCUMEN</u>	TS	1	1	Translation
Initial		Number	Date		Count	rv	Class	Subclass	
	AL		2400						
	AM						I	1	<u> </u>
	AN						1		
	AO						i		
	AP						 		
	I A.E.						!	4	
0'	THEF	R ART (Includ:	ing Author	. T:	itle, Date	Pertin	ent Pa	ges, Etc.)	
		Thierry et a	L, "Effect	of:	Liposomes	on P-q	lycopr	<u>otein Funct</u>	tion in Multi-
1 ^	ĺ	drug Resister	nt Cells,'	Bio	ochem. Biop	hys. R	es. Co	mm. 187:109	98-1105 (1992 <u>).</u>
$N \sim$	AR								
		Rahman et al	"Liposon	ne-me	ediated Mod	ulatio	n of M	ultidrug Re	esistance in
		Human HL-60 1	Leukemia (cella	s," J. Natl	. Canc	er Ins	t. 84:1909	<u>-1914 (1992). </u>
	AS								
		Mayer et al,	"Influenc	e o	f Vesicle S	<u>ize, L</u>	<u>ipid C</u>	<u>omposition</u>	, and Drug-to-
		Lipid Ratio	on the Bio	loq:	<u>ical Activi</u>	ty of	Liposo	mal Doxorul	<u> bicin in Mice,"</u>
	AT	Cancer Resear	ch 49:492	22-5	930 (1989).				
1		Acton et al,	"Intensel	y Po	otent Morph	olinyl	Anthr	acyclines,	" J. Med. Chem.
il/		27:638-645 (L984).						
\/	AU								
Examiner		Kike			Date Cons	idered	3/	19	
EXAMINER	: II	nitial if refe 9; Draw line	erence cor	sid	ered, wheth	er or	not ci	tation is	in conformance
		of this for							

with next communication to applicant.

Information Disclosure Statement--PTO-1449 (Modified)

Added page

Form PTO-1449 (Modified) List of Patents and Publications			Atty Docket No. UTSC584			Serial No.			
		it's Informat			Applicant				
		Statement							
•	_		,	Yiyı	Zou et al		Crown		
(Use seve	eral	sheets if n	ecessary)	07	Filing Date 7/24/98		Group		
				· ·	72.75	·			
Re:	fere	ence Designat	ion	Ţ	J. S. Patent Docu	ments			
Examiner		Document				-		Filing Date	
<u>Initial</u>		Number	Date		Name	Class	Subclass	If Appropriate	
	AA					 	<u> </u>	1	
	AB					 	1	<u> </u>	
	AC		<u> </u>			ļ			
	AD		<u> </u>			 			
	AE		L			<u> </u>	<u> </u>		
	AF		L			ļ			
	AG					ļ			
	AH		ļ				<u> </u>		
	AI		<u> </u>			1	J		
	AJ		<u> </u>						
	AK		İ			<u> </u>	ļ		
	1 1	Degument	FOREIGN	PATI	ENT DOCUMENTS	i	1	Translation	
Examiner Initial	1	Document Number	Date		Country	Class	Subclass		
<u> mrciur</u>	AL	Trund C1	2400						
	AM		i .			<u> </u>			
	AN								
	AO					Ì			
	AP		ĺ			1			
	1								
O'	THEF	R ART (Includ	ing Autho	r, T	itle, Date Pertin	ent Pa	ges, Etc.)		
		Priebe et al	, "Remova	l of	the Basic Center	From	<u>Doxorubici</u>		
1		Overcomes Mu	ltidrug R	<u>esist</u>	ance and Decreas	es Car	diotoxicit	y," Anticancer	
NO.	AR	Drugs 4:37-4	8 (1993).						
					and Biological C			of 4'-10do-4'-	
- 1	1	deoxydoxorub	icin," Ca	ncer	Research 47:4001	-4006	(1987).		
	AS								
		Perez-Soler	et al, "C	ellu.	lar Pharmacology	or the	<u>Partially</u>	Non-Cross-	
- 1	•				nnamycin Entrappe		iposomes 1	n KB and KB-VI	
	AT	Cells," Canc	er Resear	ch 34	4:109-118 (1994).			Timaama	
1/					I Clinical and P				
• ()/				minocycion	<u>exane-platinum</u>				
		(II)," Cance	r Researc	h 50	:4254-4259 (1990)	·			
Examiner		A A	م الم		Date Considered	`	9		
EXAMINER	: I1	nitial if ref	erence co	nsid	ered, whether or	not c	tation is	in conformance	
with MPE	P609	9; Draw line	through c	itat:	ion if not in cor	ıformaı	ice and not	considered.	
Include	copy	y of this for	m with ne	xt c	<u>ommunication to a</u> mation Disclosure	applica	ant.		
			1	nior	mation Disclosure	s scati	-01142119s A	dded page	

		49 (Modified)			Atty Docket No.		Serial No.		
		ents and Publ:			UTSC584 Applicant				
		nt's Informat: Statement	LOII		Appricant				
DISCIOSU		Jeacement		Yiv	u Zou et al				
(Use sev	era:	l sheets if ne	ecessary)		Filing Date	1	Group		
				, (07/24/98				
		ence Designat:	lon		<u>U.S. Patent Docu</u>	<u>ments</u>	1	Filing Date	
Examiner Initial	1	Document Number	Date		Name	Class	Subclace	If Appropriate	
Iniciai	AA		<u>Date</u>		Name	CIGS	Juberass	II Appropriate	
	AB	4					İ		
***************************************	•		J			 	- L		
	AC				1	 			
	AD					<u> </u>		<u></u>	
	AE					<u> </u>	<u> </u>		
	AF					<u> </u>	ļ		
	AG								
	AH					<u> </u>			
	AI				<u> </u>	l	1		
	AJ					Ì	1		
	AK				[<u> </u>		
	M						· 		
			FOREIGN	PAT	ENT DOCUMENTS				
Examiner		Document						Translation	
<u>Initial</u>		Number	Date		Country	Class	Subclass	Yes/No	
	AL					ļ			
	AM								
	AN				<u> </u>	<u> </u>			
	AO								
	AP				<u> </u>		<u> </u>		
O'	THE	R ART (Includi	ng Author	, T	<u>itle, Date Pertin</u>	ent Pa	ges, Etc.)		
					ial of Liposomal I				
)		dylethanolami	ne in Car	cer	Patients, " J. Cl:	in. On	col. 7:191	<u>5-1925 (1989).</u>	
12	AR								
1					ution and Tumor U				
		Anthracycline	<u>Derivati</u>	ve v	with High Affinit	y for	Lipid Memb	ranes,	
İ		Entrapped in	Multilame	ella	r Vesicles," Cance	er Che	mother. Pha	armacol. 32:	
	AS	190-196 (1993							
		Zou et al, "C	<u>uantitati</u>	ve .	Analysis of the L	<u>ipophi</u>	lic Doxorul	oicin Analoque	
	200				issue Samples by 1 2(11):1151-1154 (Kevers	e-Phase Ch	romatography, "	
	AI	J. Pharmaceut Gu et al, "St			olyphase Liposome		New Dosage	Form for Anti-	
-1/					Activity Screeni				
Ÿ	 	tumor Drugs.						BIDOSOMC 133	
Examiner	AU	and Others,"	Chinese F	<u>ierb</u>	Medicine, 13(4): Date Considered	13-19	1 1982).		
Examinei		le his -			Date Considered	て	100		
		- run	,		1	<u>د</u>		:	
					ered, whether or				
					ion if not in con			considered.	
Include	cop	y of this form	n with ne	kt c	<u>ommunication to a</u>	pplica	int.		

Information Disclosure Statement--PTO-1449 (Modified)
Added page

Added page

		9 (Modified) nts and Publ	ications		Atty Docket No. UTSC584		Serial No.	
For Appl:	ican	t's Informat:			Applicant	•		
Disclosu	ce S	tatement						
	_				u Zou et al	1	Croup	
(Use seve	eral	sheets if no	ecessary)	 	Filing Date 07/24/98		Group	
no.	Fara	nce Designat	ion		U. S. Patent Docu	ments		
Examiner		Document	I	·····	l	1		Filing Date
Initial	l i l i	Number	l Date		Name	Class	Subclass	If Appropriate
IIIICIAI	AA	Number	l Bass			1		
	AB		<u> </u>					
-	AC		 			1		
	AD		<u> </u>			1		
	AE		<u> </u>			1	1	
	AF		<u> </u>			1		
	AG					1	1	
	AH		<u></u>				i	
	AI		i			i		
	AJ							
	AK		<u> </u>			i	1	
	1.2.2.1		FORETGN	יים	ENT DOCUMENTS			
Examiner	1	Document	I OKDIGN			T		Translation
<u>Initial</u>		Number	Date		Country	Clas	Subclass	Yes/No
	AL		1				1	
	MA				1	- 	1	<u> </u>
	AN						1	1
	AO				1			
	AP							
0'	rhes	ART (Includ	ing Autho	r. T	itle, Date Pertir	nent P	ages, Etc.)	
		Zou et al, "	<u>Stability</u>	and	Some Other Impor	ctant	Physical Pr	operties of
/		Polysacchari	des Polyp	hase	Liposome (PPL),'	' Acta	Pharmaceut	<u>ica Sinicia,</u>
$-\omega$	AR	24(1):58-62	(1989).					
				hrac	ycline Antineopla	astic	Drugs," N.	Engl. J. Med.,
Ì	1 1	305(3):139-1	<u>53 (1981)</u>	•				
	AS		u plana	T 100 to	ial of Taxotere:	Five	-Day Schedu	le," J. Natl.
		<u>Pazdur et al</u> Cancer Inst.				FIVE	Day Schedu	10, 0
-(V)	AT							
Examiner		ka d.	1		Date Considered	i	T.1	
EXAMINED	· Tr	vitial if ref	erence co	nsid	ered, whether or	not c	itation is	in conformance
with MPE	P609	e: Draw line	through c	itat	ion if not in cor	ntorma	nce and not	considered.
Include	copy	of this for	m with ne	xt c	ommunication to	applic	ant.	